Bicycle Therapeutics plc Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
Bicycle Therapeutics plc (BCYC) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of -$2.95 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-07-30
- Bicycle Therapeutics plc increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was -$597.00K, a 106.50% decline year-over-year.
- Bicycle Therapeutics plc increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was -$2.35M.
- Bicycle Therapeutics plc increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was $2.00M, a 46.61% decline year-over-year.
- Bicycle Therapeutics plc increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was $1.12M, a 88.30% decline year-over-year.
- Bicycle Therapeutics plc increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was $4.09M, a 57.80% decline from fiscal 2024.
- Bicycle Therapeutics plc increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was $9.70M, a 304.42% increase from fiscal 2023.
- Bicycle Therapeutics plc increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was $2.40M, a 80.60% decline from fiscal 2022.
- Bicycle Therapeutics plc increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2022 was $12.36M, a 943.21% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$597.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$2.95M 10-Q · filed 2026-07-30 | -$950.00K derived: sum of 3 quarters · filed 2026-07-30 | $171.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | -$2.35M 10-Q · filed 2026-04-30 | -$353.00K derived: sum of 2 quarters · filed 2026-04-30 | $768.00K derived: sum of 3 quarters · filed 2026-04-30 | $9.95M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $3.12M derived: sum of 2 quarters · filed 2026-03-17 | $12.30M derived: sum of 3 quarters · filed 2026-07-30 | $4.09M 10-K · filed 2026-03-17 |
| 2025-09-30 | $1.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $10.30M derived: sum of 2 quarters · filed 2026-07-30 | $2.09M 10-Q · filed 2025-10-30 | $5.84M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $9.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $972.00K 10-Q · filed 2026-07-30 | $4.72M derived: sum of 3 quarters · filed 2026-07-30 | $14.30M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | -$8.21M 10-Q · filed 2026-04-30 | -$4.46M derived: sum of 2 quarters · filed 2026-04-30 | $5.12M derived: sum of 3 quarters · filed 2026-04-30 | $6.90M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $3.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $13.32M derived: sum of 2 quarters · filed 2026-03-17 | $15.11M derived: sum of 3 quarters · filed 2026-03-17 | $9.70M 10-K · filed 2026-03-17 |
| 2024-09-30 | $9.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $11.36M derived: sum of 2 quarters · filed 2025-10-30 | $5.95M 10-Q · filed 2025-10-30 | $2.27M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-06-30 | $1.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | -$3.63M 10-Q · filed 2025-08-08 | -$7.31M derived: sum of 3 quarters · filed 2026-03-17 | -$9.64M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-03-31 | -$5.41M 10-Q · filed 2025-05-01 | -$9.10M derived: sum of 2 quarters · filed 2026-03-17 | -$11.43M derived: sum of 3 quarters · filed 2026-03-17 | $116.00K derived: sum of 4 quarters · filed 2026-03-17 |
| 2023-12-31 | -$3.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$6.02M derived: sum of 2 quarters · filed 2026-03-17 | $5.53M derived: sum of 3 quarters · filed 2026-03-17 | $2.40M 10-K · filed 2026-03-17 |
| 2023-09-30 | -$2.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $9.21M derived: sum of 2 quarters · filed 2024-10-31 | $6.08M 10-Q · filed 2024-10-31 | $12.95M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $11.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $8.42M 10-Q · filed 2024-08-06 | $15.28M derived: sum of 3 quarters · filed 2025-02-25 | $17.57M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | -$3.13M 10-Q · filed 2024-05-02 | $3.74M derived: sum of 2 quarters · filed 2025-02-25 | $6.02M derived: sum of 3 quarters · filed 2025-02-25 | $11.57M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $6.87M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $9.15M derived: sum of 2 quarters · filed 2025-02-25 | $14.70M derived: sum of 3 quarters · filed 2025-02-25 | $12.36M 10-K · filed 2025-02-25 |
| 2022-09-30 | $2.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $7.83M derived: sum of 2 quarters · filed 2023-11-02 | $5.50M 10-Q · filed 2023-11-02 | $7.20M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | $5.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $3.21M 10-Q · filed 2023-08-03 | $4.92M derived: sum of 3 quarters · filed 2024-02-20 | $5.00M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | -$2.34M 10-Q · filed 2023-05-04 | -$631.00K derived: sum of 2 quarters · filed 2024-02-20 | -$549.00K derived: sum of 3 quarters · filed 2024-02-20 | $706.00K derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | $1.71M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $1.79M derived: sum of 2 quarters · filed 2024-02-20 | $3.04M derived: sum of 3 quarters · filed 2024-02-20 | $1.19M 10-K · filed 2024-02-20 |
| 2021-09-30 | $82.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $1.34M derived: sum of 2 quarters · filed 2022-11-03 | -$521.00K 10-Q · filed 2022-11-03 | $3.28M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $1.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$603.00K 10-Q · filed 2022-08-04 | $3.20M derived: sum of 3 quarters · filed 2023-02-28 | $2.18M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | -$1.86M 10-Q · filed 2022-05-05 | $1.94M derived: sum of 2 quarters · filed 2023-02-28 | $924.00K derived: sum of 3 quarters · filed 2023-02-28 | $3.44M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $3.80M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $2.78M derived: sum of 2 quarters · filed 2023-02-28 | $5.30M derived: sum of 3 quarters · filed 2023-02-28 | $4.83M 10-K · filed 2023-02-28 |
| 2020-09-30 | -$1.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $1.49M derived: sum of 2 quarters · filed 2021-11-04 | $1.03M 10-Q · filed 2021-11-04 | $789.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $2.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $2.05M 10-Q · filed 2021-08-05 | $1.81M derived: sum of 3 quarters · filed 2022-03-01 | $2.18M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | -$464.00K 10-Q · filed 2021-05-06 | -$705.00K derived: sum of 2 quarters · filed 2022-03-01 | -$338.00K derived: sum of 3 quarters · filed 2022-03-01 | -$533.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | -$241.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $126.00K derived: sum of 2 quarters · filed 2022-03-01 | -$69.00K derived: sum of 3 quarters · filed 2022-03-01 | -$852.00K 10-K · filed 2022-03-01 |
| 2019-09-30 | $367.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $172.00K derived: sum of 2 quarters · filed 2020-11-05 | -$611.00K 10-Q · filed 2020-11-05 | -$260.00K derived: sum of 4 quarters · filed 2021-03-11 |
| 2019-06-30 | -$195.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | -$978.00K 10-Q · filed 2020-08-05 | -$627.00K derived: sum of 3 quarters · filed 2021-03-11 | $1.76M derived: sum of 4 quarters · filed 2021-03-11 |
| 2019-03-31 | -$783.00K 10-Q · filed 2020-05-07 | -$432.00K derived: sum of 2 quarters · filed 2021-03-11 | $1.95M derived: sum of 3 quarters · filed 2021-03-11 | |
| 2018-12-31 | $351.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $2.73M derived: sum of 2 quarters · filed 2021-03-11 | $2.56M 10-K · filed 2021-03-11 | |
| 2018-09-30 | $2.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $2.21M 10-Q · filed 2019-11-07 | ||
| 2018-06-30 | -$177.00K 10-Q · filed 2019-08-08 | |||
| 2017-12-31 | $1.27M 10-K · filed 2020-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B |